

T Sim's

JCO8 Rec'd PCT/PTO

08 FEB 2001

5000

#3

1702.401600



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
GUSTAV GAUDERNACK, ET AL. ) : Examiner: Unassigned  
Int'l Appln. No.: PCT/NO99/00141 ) : Group Art Unit: Unassigned  
Int'l Publ'n. No.: WO 99/58564 ) :  
U.S. Appln. No.: 09/674,913 ) :  
Nat'l Entry Date: November 8, 2000 ) :  
For: FRAMESHIFT MUTANTS OF ) February 8, 2001  
BETA-AMYLOID PRECURSOR ) :  
PROTEIN AND UBIQUITIN-B ) :  
AND THEIR USE ) :

5000

Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Forms PTO-1449. Copies of the listed documents are also enclosed.

The listed documents are noted: (1) in the specification, in which case their relevance can be determined from the discussion in the specification; or in search reports issued in counterpart applications, namely (2) the Norwegian Search Report or (3) the International Search Report, in which

case their relevance can be determined from either search report.  
A copy of each search report is enclosed.


We also have listed on the PTO Form 1449,  
PCT/NO99/00143 (WO 99/58552), which is the International  
Application that is related to copending U.S. Appln. No.  
09/674,973 filed as a National Stage Application on November 8,  
2000. A copy of the PCT/NO99/00143 (WO 99/58552) document is  
enclosed.

It is respectfully requested that the above  
information be considered by the Examiner and that a copy of the  
enclosed Form PTO-1449 be returned indicating that such  
information has been considered.

In accordance with 37 C.F.R. § 1.97(b), since the  
present Information Disclosure Statement is being filed within  
three months of the entry into the national stage by  
International Application No. PCT/NO99/00141, neither a  
certification, petition, nor payment of a fee is required.  
Nevertheless, the Commissioner is authorized to charge Deposit  
Account No. 06-1205 should any fees be associated herewith. A  
duplicate of this paper is enclosed for this purpose.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

A handwritten signature in cursive script, reading "John W. Behringer". The signature is written in dark ink and is positioned above the printed name and title.

Attorney for Applicants  
John W. Behringer  
Registration No. 23,086

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

JWB/NMD/11p